329 related articles for article (PubMed ID: 22226407)
1. Can people with nonsevere major depression benefit from antidepressant medication?
Stewart JA; Deliyannides DA; Hellerstein DJ; McGrath PJ; Stewart JW
J Clin Psychiatry; 2012 Apr; 73(4):518-25. PubMed ID: 22226407
[TBL] [Abstract][Full Text] [Related]
2. Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications.
Khin NA; Chen YF; Yang Y; Yang P; Laughren TP
J Clin Psychiatry; 2011 Apr; 72(4):464-72. PubMed ID: 21527123
[TBL] [Abstract][Full Text] [Related]
3. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
[TBL] [Abstract][Full Text] [Related]
4. [Residual symptoms after a treated major depressive disorder: in practice ambulatory observatory carried out of city].
Mouchabac S; Ferreri M; Cabanac F; Bitton M
Encephale; 2003; 29(5):438-44. PubMed ID: 14615693
[TBL] [Abstract][Full Text] [Related]
5. Does inclusion of a placebo arm influence response to active antidepressant treatment in randomized controlled trials? Results from pooled and meta-analyses.
Sinyor M; Levitt AJ; Cheung AH; Schaffer A; Kiss A; Dowlati Y; Lanctôt KL
J Clin Psychiatry; 2010 Mar; 71(3):270-9. PubMed ID: 20122371
[TBL] [Abstract][Full Text] [Related]
6. Complementary and alternative medicine for major depressive disorder: a meta-analysis of patient characteristics, placebo-response rates, and treatment outcomes relative to standard antidepressants.
Freeman MP; Mischoulon D; Tedeschini E; Goodness T; Cohen LS; Fava M; Papakostas GI
J Clin Psychiatry; 2010 Jun; 71(6):682-8. PubMed ID: 20573327
[TBL] [Abstract][Full Text] [Related]
7. Patterns of depressive symptom response in duloxetine-treated outpatients with mild, moderate or more severe depression.
Shelton RC; Prakash A; Mallinckrodt CH; Wohlreich MM; Raskin J; Robinson MJ; Detke MJ
Int J Clin Pract; 2007 Aug; 61(8):1337-48. PubMed ID: 17627710
[TBL] [Abstract][Full Text] [Related]
8. Relationship between the Hamilton Depression Rating Scale and the Montgomery-Asberg Depression Rating Scale in depressed elderly: a meta-analysis.
Heo M; Murphy CF; Meyers BS
Am J Geriatr Psychiatry; 2007 Oct; 15(10):899-905. PubMed ID: 17911366
[TBL] [Abstract][Full Text] [Related]
9. Clinical use of the Hamilton Depression Rating Scale: is increased efficiency possible? A post hoc comparison of Hamilton Depression Rating Scale, Maier and Bech subscales, Clinical Global Impression, and Symptom Checklist-90 scores.
Ruhé HG; Dekker JJ; Peen J; Holman R; de Jonghe F
Compr Psychiatry; 2005; 46(6):417-27. PubMed ID: 16275208
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients.
Yevtushenko VY; Belous AI; Yevtushenko YG; Gusinin SE; Buzik OJ; Agibalova TV
Clin Ther; 2007 Nov; 29(11):2319-32. PubMed ID: 18158074
[TBL] [Abstract][Full Text] [Related]
11. Does early improvement triggered by antidepressants predict response/remission? Analysis of data from a naturalistic study on a large sample of inpatients with major depression.
Henkel V; Seemüller F; Obermeier M; Adli M; Bauer M; Mundt C; Brieger P; Laux G; Bender W; Heuser I; Zeiler J; Gaebel W; Mayr A; Möller HJ; Riedel M
J Affect Disord; 2009 Jun; 115(3):439-49. PubMed ID: 19027961
[TBL] [Abstract][Full Text] [Related]
12. Short-term efficacy and safety of desvenlafaxine in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder.
Kornstein SG; Jiang Q; Reddy S; Musgnung JJ; Guico-Pabia CJ
J Clin Psychiatry; 2010 Aug; 71(8):1088-96. PubMed ID: 20797382
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of antidepressants for late-life depression: a meta-analysis and meta-regression of placebo-controlled randomized trials.
Tedeschini E; Levkovitz Y; Iovieno N; Ameral VE; Nelson JC; Papakostas GI
J Clin Psychiatry; 2011 Dec; 72(12):1660-8. PubMed ID: 22244025
[TBL] [Abstract][Full Text] [Related]
14. Early response and remission as predictors of a good outcome of a major depressive episode at 12-month follow-up: a prospective, longitudinal, observational study.
Ciudad A; Álvarez E; Roca M; Baca E; Caballero L; García de Polavieja P; Casillas M; Valladares A; Gilaberte I
J Clin Psychiatry; 2012 Feb; 73(2):185-91. PubMed ID: 22053897
[TBL] [Abstract][Full Text] [Related]
15. Anxiety does not predict response to duloxetine in major depression: results of a pooled analysis of individual patient data from 11 placebo-controlled trials.
Nelson JC
Depress Anxiety; 2010; 27(1):12-8. PubMed ID: 20013987
[TBL] [Abstract][Full Text] [Related]
16. Metyrapone as additive treatment in major depression: a double-blind and placebo-controlled trial.
Jahn H; Schick M; Kiefer F; Kellner M; Yassouridis A; Wiedemann K
Arch Gen Psychiatry; 2004 Dec; 61(12):1235-44. PubMed ID: 15583115
[TBL] [Abstract][Full Text] [Related]
17. Parallel-group placebo-controlled trial of testosterone gel in men with major depressive disorder displaying an incomplete response to standard antidepressant treatment.
Pope HG; Amiaz R; Brennan BP; Orr G; Weiser M; Kelly JF; Kanayama G; Siegel A; Hudson JI; Seidman SN
J Clin Psychopharmacol; 2010 Apr; 30(2):126-34. PubMed ID: 20520285
[TBL] [Abstract][Full Text] [Related]
18. Correlation between different levels of placebo response rate and clinical trial outcome in major depressive disorder: a meta-analysis.
Iovieno N; Papakostas GI
J Clin Psychiatry; 2012 Oct; 73(10):1300-6. PubMed ID: 23140647
[TBL] [Abstract][Full Text] [Related]
19. Meta-analysis of placebo rates in major depressive disorder trials.
Stolk P; Ten Berg MJ; Hemels ME; Einarson TR
Ann Pharmacother; 2003 Dec; 37(12):1891-9. PubMed ID: 14632596
[TBL] [Abstract][Full Text] [Related]
20. The efficacy profile of vilazodone, a novel antidepressant for the treatment of major depressive disorder.
Reed CR; Kajdasz DK; Whalen H; Athanasiou MC; Gallipoli S; Thase ME
Curr Med Res Opin; 2012 Jan; 28(1):27-39. PubMed ID: 22106941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
